Silbersher v. Allergan plc

CourtDistrict Court, N.D. California
DecidedJanuary 28, 2021
Docket3:18-cv-03018
StatusUnknown

This text of Silbersher v. Allergan plc (Silbersher v. Allergan plc) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Silbersher v. Allergan plc, (N.D. Cal. 2021).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 ZACHARY SILBERSHER, et al., 7 Case No. 18-cv-03018-JCS Plaintiffs, 8 ORDER GRANTING MOTION TO v. CERTIFY ORDER FOR IMMEDIATE 9 APPEAL AND FOR STAY, VACATING ALLERGAN INC., et al., FEBRUARY 5, 2021 MOTION 10 HEARING AND CONTINUING Defendants. FURTHER CASE MANAGEMENT 11 CONFERENCE TO JUNE 4, 2021

12 Re: Dkt. No. 136

13 14 I. INTRODUCTION 15 Plaintiff-Relator Zachary Silbersher (“Relator”) brings this action against two sets of 16 defendants: 1) the Allergan Defendants (“Allergan”); and 2) the Adamas Defendants (“Adamas”). 17 He asserts claims under the federal False Claims Act (“FCA”), 31 U.S.C. §§ 3729-3733, based on 18 allegations that Adamas and Allergan misled the United States Patent Office (“PTO”) into issuing 19 invalid patents protecting the drugs Namenda XR® and Namzaric®, thus perpetuating their 20 monopoly power and allowing them to overcharge the federal government and the States for these 21 drugs under various programs, including Medicare and Medicaid. Adamas and Allergan brought 22 motions to dismiss, which the Court denied. Dkt. No. 135 (“December 11, 2020 Order”). 23 Defendants now bring a Motion to Certify Order for Immediate Appeal and Stay (“Motion”), 24 asking the Court to certify its December 11, 2020 Order for immediate interlocutory review under 25 28 U.S.C. § 1292(b) and to either: 1) stay the case for the duration of the appeal; or 2) stay the 26 case pending the Ninth Circuit’s decisions in United States ex rel. Silbersher v. Valeant 27 Pharmaceuticals International, Inc., No. 18-cv-1496 JD, United States District Court for the 1 Providence Health & Servs., No. CV 17-1694 PSG (SSX), United States District Court for the 2 Central District of California. (“Integra”). The Court finds that the Motion is suitable for 3 determination without oral argument and therefore vacates the hearing set for February 5, 2021 4 pursuant to Civil Local Rule 7-1(b). For the reasons stated below, the Motion is GRANTED.1 5 II. ANALYSIS 6 A. Interlocutory Appeal 7 Defendants contend the December 11, 2020 Order should be certified for interlocutory 8 appeal based on at least the following issues addressed in the Court’s Order: 9 1. Whether the PTO’s consideration of a patent prosecution is a “Federal . . . hearing, 10 audit, or investigation” within the meaning of Section 3730(e)(4)(A)(ii) of the FCA; 11 2. Whether information reported by the PTO on its public Patent Application Information 12 Retrieval website (“PAIR”) is a “Federal report” under the same subsection; and 13 3. Whether information published on the public version of PAIR qualifies as “news media” 14 as that term is used in Section 3730(e)(4)(A)(iii). 15 See Dkt. No. 136 at ECF p. 6. The Court agrees. 16 Under 28 U.S.C. § 1292(b), a federal district court may certify an order for immediate 17 interlocutory review where: (1) “the order involves a controlling question of law”; (2) “as to which 18 there is substantial ground for difference of opinion;” and (3) “an immediate appeal from the order 19 may materially advance the ultimate termination of the litigation.” 28 U.S.C. § 1292(b). By its 20 terms, § 1292(b) requires the district court to expressly find in writing that all three § 1292(b) 21 requirements are met. Id. “Section 1292(b) is a departure from the normal rule that only final 22 judgments are appealable, and therefore must be construed narrowly.” James v. Price Stern Sloan, 23 Inc., 283 F.3d 1064, 1067 n.6 (9th Cir. 2002). In seeking interlocutory appeal, a movant must 24 show that “exceptional circumstances justify a departure from the basic policy of postponing 25 appellate review until after the entry of a final judgment.” Coopers & Lybrand v. Livesay, 437 26 U.S. 463, 475 (1978). 27 1 1. Controlling Questions of Law 2 A controlling question of law “is not necessarily one that is dispositive of the litigation.” 3 Spread Your Wings, LLC v. AMZ Grp. LLC, No. 20-CV-03336-VKD, 2020 WL 7122513, at *2 4 (N.D. Cal. Dec. 4, 2020). “‘Rather, all that must be shown in order for a question to be 5 ‘controlling’ is that resolution of the issue on appeal could materially affect the outcome of 6 litigation in the district court.’” Id. (quoting In re Cement Antitrust Litig., 673 F.2d 1020, 1026 7 (9th Cir. 1981)). “Examples of such ‘controlling’ questions include ‘fundamental’ issues 8 concerning ‘the determination of who are necessary and proper parties, whether a court to which a 9 cause has been transferred has jurisdiction, or whether state or federal law shall be applied.’” Id. 10 (quoting United States v. Woodbury, 263 F.2d 784, 787 (9th Cir. 1959)). “Issues that are collateral 11 to the merits of an action may be the proper subject of a § 1292(b) appeal, see In re Cement 12 Antitrust Litig., 673 F.2d at 1027 n.5, and ‘an order may involve a controlling question of law if it 13 could cause the needless expense and delay of litigating an entire case in a forum that has no 14 power to decide the matter,’ Kuehner v. Dickinson & Co., 84 F.3d 316, 319 (9th Cir. 1996).” Id. 15 “The controlling question of law in an interlocutory appeal generally is a purely legal one that can 16 be resolved quickly without delving into a particular case’s facts.” Henley v. Jacobs, No. C 18- 17 2244 SBA, 2019 WL 8333448, at *2 (N.D. Cal. Oct. 25, 2019) (citing Steering Comm. v. United 18 States, 6 F.3d 572, 575-76 (9th Cir. 1993)). 19 The Court concludes that the issues identified by Defendants are controlling questions of 20 law. While it is true that Relator’s claims could escape the public disclosure bar if he is found to 21 have been an “original source” – an issue the Court did not address – the legal questions the Court 22 decided with respect to whether the disclosures were made via a permissible channel could 23 nonetheless materially affect the outcome of the litigation. Likewise, the Court’s conclusions that 24 the disclosures in this case fell outside the ambit of the public disclosure bar, if reversed on appeal, 25 would cause needless expense and delay litigating a case where Relator’s claims are barred if an 26 immediate appeal is not permitted. Therefore, the Court finds that this requirement is satisfied. 27 2. Ground for Difference of Opinion 1 on an issue’s resolution, not merely where they have already disagreed.” Reese v. BP Exploration 2 (Alaska) Inc., 643 F.3d 681, 688 (9th Cir. 2011). “Courts traditionally will find that a substantial 3 ground for difference of opinion exists where ‘the circuits are in dispute on the question and the 4 court of appeals of the circuit has not spoken on the point, if complicated questions arise under 5 foreign law, or if novel and difficult questions of first impression are presented.’” Couch v. 6 Telescope Inc., 611 F.3d 629, 633 (9th Cir. 2010) (citation omitted).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

President of the Bank of Columbia v. Hagner
26 U.S. 455 (Supreme Court, 1828)
Couch v. Telescope Inc.
611 F.3d 629 (Ninth Circuit, 2010)
Leiva-Perez v. Holder
640 F.3d 962 (Ninth Circuit, 2011)
Reese v. BP Exploration (Alaska) Inc.
643 F.3d 681 (Ninth Circuit, 2011)
United States v. Ray B. Woodbury
263 F.2d 784 (Ninth Circuit, 1959)
United States v. Adam Bros. Farming, Inc.
369 F. Supp. 2d 1180 (C.D. California, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
Silbersher v. Allergan plc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/silbersher-v-allergan-plc-cand-2021.